Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-12
2006-09-12
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S350000, C530S399000, C530S402000
Reexamination Certificate
active
07105480
ABSTRACT:
The present invention relates generally to a method of modulating bone resorption and to agents useful for same. More particularly, the present invention provides for the use of leptin and its derivatives, homologues, analogues, antagonists or agonists to modulate osteoclastogenesis. Even more particularly, the present invention contemplates the treatment of disorders characterised by or associated with excessive bone resorption such as but not limited to osteoporosis and Paget's disease. The present invention further provides for the use of leptin and its derivatives, homologues, analogues, antagonists and agonists in the manufacture of a medicament for the modulation of bone resorption.
REFERENCES:
patent: 6352970 (2002-03-01), Ke et al.
Liu et al. American Society for Bone and Mineral Research, 19th Annual Meeting, Sep. 10-14, 1997, Cincinati, Ohio.
Auwerx et al. “Leptin”Lancet1998; 351: 737-742.
Bonner & Laskey, “A Film Detection Method for Tritium Labelled Proteins and Nucleic Acids in Polyacrylamide Gels”Eur. J. Biochem.1974; 46: 83-88.
Friedman et al., “Leptin and the regulation of body weight in mammals”Nature1998; 395: 763-770.
Marmur & Doty, “Determination of the Base Composition of Deoxyribonucleic Acid from its Thermal Denaturation Temperature”J. Mol. Biol.1962; 5: 109-118.
Matsuzaki et al., “Osteoclast Differentiation Factore (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell Cultures”,Biochem. Biophys. Res. Commun.1998; 246: 199-204.
Quinn et al., “A Combination of Osteoclast Differentiation Factor and Macrophage-Colony Stimulating Factor is Sufficient for both Human and Mouse Osteoclast Formation in Vitro”,Endocrinology1998; 139: 4424-4427.
Simonet et al., “Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density”,Cell1997; 89: 309-319.
Suda et al. “Modulation of Osteoclast Differentiation”Endocrine Reviews1992; 13: 66-80.
Suda et al. “Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families”Endocrine Reviews1999; 20: 345-357.
Yasuda et al. “Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanismm by which OPG/OCIF Inhibits Osteoclastogenesisin Vitro” Endocrinology1998; 139: 1329-1337.
Knobbe Martens Olson & Bear LLP
Saoud Christine J.
The University of Melbourne
LandOfFree
Method of treatment and agents useful for same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment and agents useful for same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment and agents useful for same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3589447